Clinical trial
Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)
NCT00184717 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00184717 |
|---|---|
| Title | Growth Hormone Treatment in Children Born Small for Gestational Age (SGA) |
| Official title | GHLIQUID-1516: A 104-week, Multi-centre, Randomised, Double-blind, Parallel-group, no Treatment Controlled (Open-label) Trial Investigating the Efficacy and Safety of Two Doses of NN-220 in Subjects With Short Stature Born Small for Gestational Age / GHLIQUID-1517: A Long-term, Multi-centre… |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Foetal Growth Problem, Small for Gestational Age |
| Intervention type | Drug |
| Interventions | somatropin |
| Enrollment | 98 |
| Start date | Aug 18, 2004 |
| Primary completion | Mar 29, 2006 |
| Completion | Dec 28, 2009 |
| First posted | Sep 16, 2005 |
| Last update posted | Jul 7, 2017 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: